Search hospitals > North Carolina > Pinehurst
FirstHealth of the Carolinas-Moore Regional Hospital
Claim this profilePinehurst, North Carolina 28374
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Ovarian Cancer
154 reported clinical trials
3 medical researchers
Summary
FirstHealth of the Carolinas-Moore Regional Hospital is a medical facility located in Pinehurst, North Carolina. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer, Ovarian Cancer and other specialties. FirstHealth of the Carolinas-Moore Regional Hospital is involved with conducting 154 clinical trials across 265 conditions. There are 3 research doctors associated with this hospital, such as Charles S. Kuzma, John W. Byron, and Stephen C. King.Area of expertise
1Lung Cancer
Global LeaderStage II
Stage IV
Stage III
2Breast Cancer
Global LeaderER positive
HER2 positive
ER negative
Top PIs
Charles S. KuzmaFirstHealth of the Carolinas-Moore Regional Hospital6 years of reported clinical research
Expert in Lung Cancer
Expert in Breast Cancer
53 reported clinical trials
112 drugs studied
John W. ByronFirstHealth of the Carolinas-Moore Regional Hospital13 years of reported clinical research
Studies Fallopian Tube Cancer
Studies Ovarian Cancer
2 reported clinical trials
7 drugs studied
Stephen C. KingFirstHealth of the Carolinas-Moore Regional Hospital6 years of reported clinical research
Studies Prostate Adenocarcinoma
1 reported clinical trial
1 drug studied
Clinical Trials running at FirstHealth of the Carolinas-Moore Regional Hospital
Lung Cancer
Esophageal cancer
Breast Cancer
Non-Small Cell Lung Cancer
Breast cancer
Cancer
Small Cell Lung Cancer
Bladder Cancer
Esophageal Cancer
Stomach Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Durvalumab
for Lung Cancer
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.
Recruiting2 awards Phase 38 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at FirstHealth of the Carolinas-Moore Regional Hospital?
FirstHealth of the Carolinas-Moore Regional Hospital is a medical facility located in Pinehurst, North Carolina. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer, Ovarian Cancer and other specialties. FirstHealth of the Carolinas-Moore Regional Hospital is involved with conducting 154 clinical trials across 265 conditions. There are 3 research doctors associated with this hospital, such as Charles S. Kuzma, John W. Byron, and Stephen C. King.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.